Results 41 to 50 of about 2,566,443 (193)

SLC2A9 is a high-capacity urate transporter in humans [PDF]

open access: yes, 2008
Background Serum uric acid levels in humans are influenced by diet, cellular breakdown, and renal elimination, and correlate with blood pressure, metabolic syndrome, diabetes, gout, and cardiovascular disease. Recent genome-wide association scans have
Doblado M   +240 more
core   +1 more source

Modulation of genetic associations with serum urate levels by body-mass-index in humans [PDF]

open access: yes, 2015
We tested for interactions between body mass index (BMI) and common genetic variants affecting serum urate levels, genome-wide, in up to 42569 participants.
Döring, Angela   +999 more
core   +3 more sources

Probabilistic sensitivity analysis for urate lowering therapy combined with naproxen.

open access: yes, 2022
Probabilistic sensitivity analysis for urate lowering therapy combined with naproxen.
Carly A. Janssen (12015373)   +5 more
core   +1 more source

Cardiac and renal protective effects of urate-lowering therapy [PDF]

open access: yesRheumatology, 2017
Patients with gout often have co-morbidities such as cardiovascular disease, renal failure and metabolic syndrome components. Some studies, but not all, have suggested that hyperuricaemia and gout are associated with increased risk of myocardial infarction, renal failure and death primarily because of increased risk of cardiovascular events. Therefore,
Pascal, Richette   +2 more
openaire   +2 more sources

Bariatric surgery as urate-lowering therapy in severe obesity [PDF]

open access: yesAnnals of the Rheumatic Diseases, 2014
Gout represents a metabolically driven inflammatory arthropathy, which could be substantially influenced by adiposity and lifestyle risk factors. As such, influenced by the trends in lifestyle factors associated with Westernisation,1 ,2 gout prevalence has increased in the last few decades worldwide (eg, 3.9% of US adults (8.3 million) in 2007–20083).4
Hyon K, Choi, Yuqing, Zhang
openaire   +2 more sources

Depressive Symptoms and the Effectiveness of a Urate‐Lowering Therapy in a Clinical Trial [PDF]

open access: yesACR Open Rheumatology, 2020
ObjectiveThis ancillary study examined the impact of depressive symptoms on the effectiveness of a urate‐lowering therapy in the context of a clinical trial.MethodsParticipants included 67 adults (ages 18–40) with elevated blood pressure who were enrolled in a double‐blind, randomized, crossover clinical trial evaluating the effectiveness of ...
Sylvie Mrug   +6 more
openaire   +3 more sources

Implication of nurse intervention on engagement with urate-lowering drugs: a qualitative study of participants in a RCT of nurse led care [PDF]

open access: yes, 2019
Objectives To explore patient perception of the role of a nurse-led complex package of care in facilitating engagement with urate-lowering therapies (ULTs) in the management of gout.Methods Thirty people who had participated in a randomised controlled ...
Abhishek, Abhishek   +4 more
core   +1 more source

Variation in serum urate levels in the absence of gout and urate lowering therapy

open access: yesBMC Rheumatology, 2021
Background Previous studies have noted significant variation in serum urate (sUA) levels, and it is unknown how this influences the accuracy of hyperuricemia classification based on single data points.
Andrew Shaffer   +4 more
doaj   +1 more source

Risk of fragility fracture among patients with gout and the effect of urate-lowering therapy [PDF]

open access: yes, 2018
BACKGROUND: Previous studies that quantified the risk of fracture among patients with gout and assessed the potential effect of urate-lowering therapy have provided conflicting results. Our study aims to provide better estimates of risk by minimizing the
Mallen   +6 more
core   +2 more sources

Urate-Lowering Therapy in Moderate to Severe Chronic Kidney Disease [PDF]

open access: yesThe Permanente Journal, 2018
Hyperuricemia is an independent risk factor for progression of kidney disease.To determine whether lowering serum uric acid level (sUA) to below 6 mg/dL (target) improves mild to moderate chronic kidney disease (CKD) and whether CKD stage influences the benefit of lowering sUA to target.Retrospective epidemiologic cohort study conducted over 8 years ...
Gerald, Levy   +3 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy